Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
Casirivimab
Novel compound
Emergency use authorization Experimental Antiviral Jan/23/2023
T cells
Novel compound
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Jan/18/2023
Anti-spike nanobody-IFN-β conjugated exosomes
Novel compound
Potential treatment - pre-clinical evidence Experimental Antiviral Sep/26/2022
IMAT-MSCs
Novel compound
Potential treatment - pre-clinical evidence Experimental Other treatment Sep/23/2022
Exosomal vaccine
Novel compound
Potential treatment - pre-clinical evidence Experimental Vaccine Jul/29/2022
EXO-CD24
Novel compound
Potential treatment - clinical evidence Experimental Other treatment Jul/13/2022
Nirmatrelvir
Novel compound
Emergency use authorization Experimental Antiviral Jun/23/2022
Etesevimab
Novel compound
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
Bebtelovimab
Novel compound
Emergency use authorization Experimental Antiviral Jun/18/2022
P2C-1F11
Novel compound
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/25/2022
PDA@Exosome
Novel compound
Potential treatment - pre-clinical evidence Experimental Other treatment Jan/22/2022
S2K146
Novel compound
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/06/2022
mAb 222
Novel compound
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb Beta-55
Novel compound
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb Beta-29
Novel compound
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb 58
Novel compound
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb Beta-54
Novel compound
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb 253
Novel compound
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb Beta-53
Novel compound
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb Beta-47
Novel compound
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022